MarketCap
Facebook
X
Telegram
FSD Pharma Balance Sheet 2025-2011 | HUGE
Brief overview of FSD Pharma 's assets and capital
This overview follows the five latest available annual observations between 2021 and 2025.
Assets declined from $63 million to $11.2 million, or -82.3%. The contraction calls for context such as disposals, restructuring or weaker operations.
Funding shifted toward liabilities: they gained -31.4%, compared with -82.3% for assets.
Equity finances 45.7% of the balance sheet, compared with at the start. The cushion remains adequate.
The cash reserve occupies 17.1% of the balance sheet, previously 56%. It is one marker of short-term resilience.
The accumulated result is -$198.3 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
FSD Pharma 's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet FSD Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -16.8 M | - | -17 M | -5.88 M | -21.1 M | 17.3 K | -9.34 K | 23.9 K | - | - | - | - |
Long Term Debt |
- | - | - | 38 K | - | - | 147 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
103 K | 53.8 K | 38.6 K | 178 K | 124 K | 46.8 K | 40.9 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 79.1 K | 147 K | - | - | - | - | - | - | - | - |
Total Liabilities |
6.06 M | 6.68 M | 4.57 M | 7.87 M | 8.83 M | 5.66 M | 9.23 M | 1.74 M | 113 K | 80.4 K | 80.2 K | - | - | - | - |
Retained Earnings |
-198 M | -172 M | -158 M | -144 M | - | -90.9 M | -72.8 M | -26.5 M | -1.73 M | -1.7 M | -1.66 M | - | - | - | - |
Total Assets |
11.2 M | 17.1 M | 17.5 M | 38.4 M | 63 M | 42 M | 57.4 M | 52.8 M | 17.7 K | 9.34 K | 2.86 K | - | - | - | - |
Cash and Cash Equivalents |
1.91 M | 6 M | 2.76 M | 17 M | 35.3 M | 17.5 M | 5.97 M | 15.9 M | - | - | - | - | - | - | - |
Book Value |
5.1 M | 10.4 M | 12.9 M | 30.5 M | 54.1 M | 36.3 M | 48.2 M | 51 M | -95.5 K | -71.1 K | -77.3 K | - | - | - | - |
Total Shareholders Equity |
5.1 M | 10.4 M | 12.9 M | 30.5 M | - | 36.3 M | 36.3 M | 38.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet FSD Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | 131 K | - | - | - | 79.1 K | - | - | - | 110 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.06 M | 6.65 M | 13.2 M | 10.3 M | 6.68 M | 3.68 M | 5.04 M | 4.57 M | - | - | - | - | 8.83 M | - | - | - | 5.66 M | - | - | - | 6.94 M | - | - | - | 1.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-198 M | -195 M | -190 M | -181 M | -172 M | -167 M | -163 M | -158 M | - | - | - | - | -126 M | - | - | - | -90.9 M | - | - | - | -59.1 M | - | - | - | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
11.2 M | 14.2 M | 15.3 M | 14.9 M | 17.1 M | 19 M | 15.2 M | 17.5 M | - | - | - | - | 63 M | - | - | - | 42 M | - | - | - | 43.2 M | - | - | - | 39.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.91 M | 446 K | 1.5 M | 3.52 M | 6 M | 3.12 M | 3.31 M | 2.76 M | - | - | - | - | 35.3 M | - | - | - | 17.5 M | - | - | - | 5.97 M | - | - | - | 15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
5.1 M | 7.51 M | 2.05 M | 4.53 M | 10.4 M | 15.3 M | 10.2 M | 12.9 M | - | - | - | - | 54.1 M | - | - | - | 36.3 M | - | - | - | 36.3 M | - | - | - | 38.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
5.1 M | 7.51 M | 2.05 M | 4.53 M | 10.4 M | 15.3 M | 10.2 M | 12.9 M | - | - | - | - | 54.1 M | - | - | - | 36.3 M | - | - | - | 36.3 M | - | - | - | 38.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of FSD Pharma , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
China
Israel
France
Germany
Britain
Russia
Belgium
Canada
Cayman-islands
